Last reviewed · How we verify
switching to different class of antidepressant — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
switching to different class of antidepressant (switching to different class of antidepressant) — Korea University.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| switching to different class of antidepressant TARGET | switching to different class of antidepressant | Korea University | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- switching to different class of antidepressant CI watch — RSS
- switching to different class of antidepressant CI watch — Atom
- switching to different class of antidepressant CI watch — JSON
- switching to different class of antidepressant alone — RSS
Cite this brief
Drug Landscape (2026). switching to different class of antidepressant — Competitive Intelligence Brief. https://druglandscape.com/ci/switching-to-different-class-of-antidepressant. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab